ClinicalTrials.gg
CompletedNCT00358644Updated May 20, 2013Results posted

Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

A Phase 2 interventional study of Decitabine in Acute Myeloid Leukemia, sponsored by Eisai Inc.. Completed at 3 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2013-05-20.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.

Enrollment
36th of 120
55 · median 32
Started
2005
with 3 others
Phase 2
53 of 121
10 open now
Registered
7th of 121
by date
Lead sponsor
4 of 121
Eisai Inc.

Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 36th largest by enrollment of the 120 interventional ones that give a count, is one of 4 that started in 2005, is one of 53 in phase 2, and was the 7th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing decitabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • AML
  • Decitabine
  • Dacogen
  • MGI PHARMA, INC.
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of AML or transformed from myelodysplastic syndrome (MDS) within 2 weeks of study enrollment.
  2. Ineligible to receive intensive chemotherapy for their disease.
  3. Have not received any chemotherapy within 4 weeks of study enrollment and must have recovered from any treatment-related toxicities.

Exclusion criteria

Exclusion Criteria:

  1. Received previous treatment for AML.
  2. Previously received Vidaza.
  3. Received any other agents within 30 days of first dose of study drug.
  4. Uncontrolled intercurrent illness.
  5. Had radiotherapy within 14 days prior to study enrollment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    1

    Drug: Decitabine

Interventions

  • 20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.

    Also known as: Dacogen

06

What researchers measure

Primary outcomes

  1. Complete Response = Morphologic Complete Remission (mCR)

    Time frame: 1 year

07

Results

Posted Sep 7, 2009

Participant flow

Participant flow — Overall Study
MilestoneDecitabine 20 mg/m2 Intravenous
Started55
Completed5
Not completed50
Withdrew: Progressive disease21
Withdrew: Adverse event7
Withdrew: Death11
Withdrew: Withdrawal by subject4
Withdrew: Physician decision6
Withdrew: Patient not eligible for study1

Outcome measures

PrimaryComplete Response = Morphologic Complete Remission (mCR)
Time frame:
1 year
Reported as:
Number · Participants
Complete Response = Morphologic Complete Remission (mCR)
ParticipantsDecitabine 20 mg/m2 Intravenous
Complete Response = Morphologic Complete Remission (mCR)13
Statistical analysis
  • Decitabine 20 mg/m2 Intravenous · Percentage of participants: 23.6 · 95% CI 13.2 to 37.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Decitabine 20 mg/m2 Intravenous—40/55 (72.7%)55/55 (100%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventDecitabine 20 mg/m2 Intravenous
Febrile NeutropeniaBlood and lymphatic system disorders13/55
Disease ProgressionGeneral disorders9/55
SepsisInfections and infestations8/55
PneumoniaInfections and infestations7/55
BacteraemiaInfections and infestations6/55
NeutropeniaBlood and lymphatic system disorders4/55
PyrexiaGeneral disorders4/55
Clostridium Difficile ColitisInfections and infestations4/55
Urinary Tract InfectionInfections and infestations4/55
DiarrheaGastrointestinal disorders3/55
Most frequent other events
Showing 10 of 94
Most frequent other events
EventDecitabine 20 mg/m2 Intravenous
FatigueGeneral disorders37/55
NauseaGastrointestinal disorders28/55
PyrexiaGeneral disorders24/55
ConstipationGastrointestinal disorders23/55
DiarrheaGastrointestinal disorders22/55
DyspnoeaRespiratory, thoracic and mediastinal disorders22/55
Oedema PeripheralGeneral disorders20/55
Febrile NeutropeniaBlood and lymphatic system disorders17/55
AstheniaGeneral disorders17/55
VomitingGastrointestinal disorders16/55

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Decitabine 20 mg/m2 Intravenous
<=18 years0
Between 18 and 65 years7
>=65 years48
Age Continuous
Age Continuous(years)Decitabine 20 mg/m2 Intravenous
Mean73.0 ± 6.84
Sex: Female, Male
Sex: Female, Male(Participants)Decitabine 20 mg/m2 Intravenous
Female28
Male27
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Decitabine 20 mg/m2 Intravenous
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White50
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Decitabine 20 mg/m2 Intravenous
United States55
08

Study locations

3 sites
  • Duarte, California 91010, United States
  • Los Angeles, California 90095-1678, United States
  • St. Louis, Missouri 63110, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Feb 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2006
First posted
Aug 1, 2006
Start
Mar 2005
Primary completionActual
Feb 2008
CompletionActual
Dec 2008
Results first posted
Sep 7, 2009
Last update
May 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00358644
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Aug 1, 2006
Start date
Mar 2005
Primary completion
Feb 2008
Completion
Dec 2008
Results posted
Sep 7, 2009
Last update
May 20, 2013

Study contacts

Eisai US Medical Services
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion